0000000000339175

AUTHOR

Salvatore Mangione

showing 27 related works from this author

Effects of antithrombin III (ATIII) treatment (high dose) in severe pre-eclampsia and HELLP syndrome with alterations of coagulation inhibitors and i…

2000

medicine.medical_specialtyEclampsiaProteinuriabusiness.industryHELLP syndromeAntithrombinCritical Care and Intensive Care Medicinemedicine.diseaseBioinformaticsGastroenterologyCoagulationPreliminary reportInternal medicineMeeting AbstractMedicinemedicine.symptombusinessmedicine.drug
researchProduct

The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.

2010

OBJECTIVES: To determine the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP). METHODS: In 66 patients consecutive patients admitted to a pain relief and palliative care unit, the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP) were assessed. The choice of the opioid to be administered as rescue medication was based on the characteristics of patients, clinical stability, compliance, preference, and so on. For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging prob…

MalePalliative careBreakthrough PainAdministration OralPainDrug Administration ScheduleSex FactorsClinical ProtocolsMedicinebreakthrough pain; acute palliative care unit; opioidsHumansAgedPain MeasurementAnalgesicsDose-Response Relationship Drugbusiness.industryPalliative CareAge FactorsopioidsMiddle Agedacute palliative care unitbreakthrough painClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineNociceptionTreatment OutcomeBasal (medicine)OpioidAnesthesiaFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

Tassonomia del Dolore.

2006

researchProduct

Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.

2007

The use of symptomatic agents has greatly improved the medical treatment of advanced cancer patients with inoperable bowel obstruction. A systematic review of studies of the most popular drugs used in the medical management of inoperable malignant bowel obstruction was performed to assess the effectiveness of these treatments and provide some lines of evidence. Randomized trials that involved patients with a clinical diagnosis of intestinal obstruction due to advanced cancer treated with these drugs were reviewed. Five reports fulfilled inclusion criteria. Three studies compared octreotide (OC) and hyoscine butylbromide (HB), and two studies compared corticosteroids (CSs) and placebo. Globa…

medicine.medical_specialtymedicine.drug_classPopulationOctreotideMuscarinic AntagonistsPlaceboSettore MED/42 - Igiene Generale E ApplicataOctreotidelaw.inventionRandomized controlled trialGastrointestinal AgentslawAdrenal Cortex HormonesInternal medicineNeoplasmsButylscopolammonium BromidemedicineHumansStage (cooking)educationinoperable malignant bowel obstruction treatmentGeneral Nursingeducation.field_of_studybusiness.industryqualitative systematic reviewCancermedicine.diseaseSurgeryBowel obstructionAnesthesiology and Pain Medicineinoperable malignant bowel obstruction treatment; qualitative systematic review; management of bowel obstructionCorticosteroidNeurology (clinical)businessIntestinal Obstructionmedicine.drugmanagement of bowel obstructionJournal of pain and symptom management
researchProduct

La coagulopatia nel Paziente critico: le dimensioni del problema

2005

researchProduct

Clinical and financial analysis of an acute palliative care unit in an oncological department

2008

The aim of this article is to describe the clinical activity and medical intervention of an acute model of palliative care unit (APC), as well as the reimbursement procedures and economic viability. A sample of 504 patients admitted at an APC in 1 year was surveyed. Indications for admission, pain and symptom intensity, analgesic treatments, procedures, instrumental examinations and modalities of discharge were recorded. For each patient, tariff for reimbursement was calculated according to the existent disease related grouping (DRG) system. The mean age was 62 years, and 246 patients were males. The mean hospital stay was 5.4 days. Pain control was the most frequent indication for admissi…

Malemedicine.medical_specialtyPalliative carePainSettore MED/42 - Igiene Generale E ApplicataUnit (housing)Economic viabilityIntervention (counseling)NeoplasmscostmedicineFinancial analysisTerminal careHumansProspective StudiesIntensive care medicinepain and symptom controlReimbursementCancerTerminal Carepalliative carebusiness.industryDelivery of Health Care IntegratedGeneral MedicineMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineTreatment OutcomeItalyEmergency medicineInsurance Health ReimbursementFemaleOpioid analgesicsbusinessErythrocyte TransfusionDelivery of Health Care
researchProduct

Home Palliative Care: The Challenge in Palermo

1990

Palliative careNursingbusiness.industryMedicineGeneral MedicinebusinessJournal of Palliative Care
researchProduct

Antithrombin III and Activated Protein C for the treatment of severe sepsis with coagulopathy

2006

sepsisAT IIISettore MED/41 - AnestesiologiaaPC
researchProduct

Patologie Coagulative in Ostetricia

2005

researchProduct

Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.

2007

The aim of this study was to prospectively evaluate the frequency, indications, outcomes, and predictive factors associated with opioid switching, using a protocol that had been clinically applied and viewed as effective for many years. A prospective study was carried out on a cohort of consecutive cancer patients who were receiving opioids but had an unacceptable balance between analgesia and adverse effects, despite symptomatic treatment of side effects. The initial conversion ratio between opioids and routes was as follows (mg/day): oral morphine 100=intravenous morphine 33=transdermal fentanyl 1=intravenous fentanyl 1=oral methadone 20=intravenous methadone 16=oral oxycodone 70=transder…

AdultMalePalliative carePainFentanylpredictive factoropioid switchingMedicineHumansProspective StudiesOpioid peptideAdverse effectGeneral NursingAgedMorphinebusiness.industryPalliative Careacute palliative care unitMiddle AgedBuprenorphineAnalgesics OpioidFentanylAnesthesiology and Pain MedicineTreatment OutcomeOpioidAnesthesiaFemaleNeurology (clinical)businessCancer painOxycodoneMethadonemedicine.drugMethadoneJournal of pain and symptom management
researchProduct

ALTERNATIVE TREATMENTS OF BREAKTHROUGH PAIN IN PATIENTS RECEVEING SPINAL ANALGESICS FOR CANCER PAIN.

2005

researchProduct

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

2008

The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone.One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 microg/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week interva…

MaleCost-Benefit AnalysisAdministration OralFentanylNeoplasmscancer pain opioidsProspective StudiesCancer painTransdermalIntractableAnalgesicsMorphineMiddle AgedPain IntractableAnalgesics OpioidFentanylNeuropsychology and Physiological PsychologyTreatment OutcomeNeurologyPatient SatisfactionAnesthesiaAdministrationFemaleDrugmedicine.drugOralAdultAdolescentAnalgesicPainOpioidAdministration CutaneousDrug Administration ScheduleDose-Response RelationshipmedicineHumansAdverse effectAgedDose-Response Relationship Drugbusiness.industryCostsCutaneousAnesthesiology and Pain MedicineOpioidCancer pain; Costs; Fentanyl; Methadone; Morphine; Administration Cutaneous; Administration Oral; Adolescent; Adult; Aged; Analgesia; Analgesics Opioid; Cost-Benefit Analysis; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Fentanyl; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain Intractable; Patient Satisfaction; Prospective Studies; Quality of Life; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neuropsychology and Physiological PsychologyMorphineQuality of LifeAnalgesiaCancer painbusinessMethadoneMethadoneEuropean journal of pain (London, England)
researchProduct

CLINICAL RESEARCH IN ITALY IN ADULT PATIENTS UNABLE TO CONSENT: AFTER IMPLEMENTATION OF THE EUROPEAN UNION'S DIRECTIVE 2001/20/CE.

2007

Clinical research in Italy in adult patients unable to consent: after implementation of the European Union's Directive 2001/20/CE.

intensive care medicine end life treatment
researchProduct

Switching from Transdermal Drugs: An Observational "N of 1" Study of Fentanyl and Buprenorphine

2007

The aim of this study was to confirm that the concomitant presence of transdermal fentanyl (TTS FE) and buprenorphine (TTS BU) may be feasible without important consequences, using doses presumed to be equianalgesic. A prospective "N of 1" study was carried out in a sample of volunteers with cancer pain receiving stable doses of TTS FE or TTS BU, with adequate pain and symptom control. In the study design, each patient provided data before and after a switch from one opioid to the other and then back to the previous one. Sixteen patients receiving daily stable doses of 0.6 or 1.2 mg of TTS FE were switched to TTS BU using an FE-BU ratio of 0.6-0.8. After three days, the TTS BU patch was rem…

OralAdultMaletransdermal buprenorphinePainAdministration OralOpioidAdministration CutaneousFentanylopioid switchingNeoplasmsMedicineHumansDosingProspective StudiesCancer painNursing (all)2901 Nursing (miscellaneous)General NursingTransdermalAgedPain MeasurementIntractableAnalgesicsbusiness.industryMiddle AgedEquianalgesictransdermal fentanylBuprenorphinePain IntractableAnalgesics OpioidFentanylCutaneousAnesthesiology and Pain MedicineNeurologyOpioidConcomitantAnesthesiaCancer pain; opioid switching; transdermal buprenorphine; transdermal fentanyl; Administration Oral; Adult; Aged; Analgesics Opioid; Buprenorphine; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Prospective Studies; Administration Cutaneous; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)AdministrationFemaleNeurology (clinical)businessCancer painmedicine.drugBuprenorphine
researchProduct

Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.

2007

The aim of this prospective cohort study was to confirm the safety of intravenous morphine (IV-M) used in doses proportional to the basal opioid regimen for the management of breakthrough pain and to record the nurse compliance on regularly recording data regarding breakthrough pain treated by IV-M. Over a one-year period, 99 patients received IV-M for breakthrough pain during 116 admissions. The IV-M dose was 1/5 of the oral daily dose, converted using an equianalgesic ratio of 1/3 (IV/oral). For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (T0), and to reassess the patient 15minutes after IV-M injection (…

MalePalliative carePainCancer pain breakthrough-episodic pain intravenous morphineMedicineHumansProspective StudiesAdverse effectProspective cohort studyGeneral NursingAgedMorphinebusiness.industryPalliative CareMiddle AgedEquianalgesicClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineOpioidAnesthesiaInjections IntravenousFemaleNeurology (clinical)businessCancer painmedicine.drugJournal of pain and symptom management
researchProduct

La preeclampsia severa nella paziente critica ostetrica quale modello di patologia del sistema coagulativo-infiammatorio: presupposti teorici e risvo…

2004

researchProduct

Il razionale nell'utilizzo della Proteina C in pazienti affette da patologia ostetrica associata ad alterata risposta del sistema coagulativo e infia…

2005

researchProduct

SIAARTI RECOMMENDATIONS FOR ANALGO-SEDATION IN INTENSIVE CARE UNIT

2006

researchProduct

A Prospective Randomized Study of Corticosteroids as Adjuvant Drugs to Opioids in Advanced Cancer Patients

2007

This randomized controlled study evaluated the role of corticosteroids as adjuvants to opioid therapy in 76 advanced cancer patients with pain who requiring strong opioids. Patients were divided in 2 groups. Group O received conventional opioid treatment. Group OS received dexamethasone (8 mg orally) along with conventional treatment. Pain and symptom intensity, sense of well-being, and opioid escalation index and distress score were recorded at weekly intervals until death. No differences in pain intensity, opioid consumption, and opioid escalation index were found in 66 patients who survived 33 to 37 days. Corticosteroids did not provide significant additional analgesia to opioids, but p…

AdultMalecorticosteroidmedicine.medical_treatmentAnti-Inflammatory Agentslaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trial030502 gerontologylawNeoplasmsmedicineHumansProspective Studiesopioids in advanced cancer patientsprospective randomized studyProspective cohort studyDexamethasoneAgedPain MeasurementAged 80 and overAnalysis of VarianceChemotherapyadjuvant drugDose-Response Relationship Drugbusiness.industryPalliative CareGeneral MedicineMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidChemotherapy Adjuvant030220 oncology & carcinogenesisAnesthesiaDrug Therapy CombinationFemale0305 other medical scienceCancer painbusinessAdjuvantFollow-Up Studiesmedicine.drugAmerican Journal of Hospice and Palliative Medicine®
researchProduct

Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients.

2009

Neuropathic pain (NP) is a difficult issue, particularly in cancer which is a dynamic condition where multiple pain etiologies are concomitantly present. Cancer pain is often labeled as mixed mechanism pain and is not easily classified as exclusively nociceptive or NP. The aim of this study was to explore the value of evaluation tools such as Neuropathic Pain Questionnaire (NPQ), complete and short form (NPQ-SF), Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) and Neuropathic Pain Symptom Inventory (NPSI). The secondary outcome was to evaluate the response to opioid titration, according to the hierarchical classification of definite, possible and unlikely NP. A consecutive sample…

Malemedicine.medical_specialtyPainOpioidSensitivity and SpecificityRoute of administrationassessment toolsInternal medicineNeoplasmsmedicineassessment tools; Cancer pain; neuropathic pain; opioid response; Aged; Analgesics Opioid; Female; Humans; Male; Neoplasms; Pain; Pain Measurement; Sensitivity and Specificity; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neurology (clinical)HumansCancer painAgedPain Measurementtools for cancer painneuropathic painopioid responsivenessAnalgesicsbusiness.industryCancerPain scaleneuropathic cancer painmedicine.diseaseAnalgesics OpioidAnesthesiology and Pain MedicineNociceptionTreatment OutcomeNeurologyOpioidopioid responseAnesthesiaNeuropathic painEtiologyFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Epidemiologia delle sepsi fungine

2004

researchProduct

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain

2007

The use of supplemental doses of opioids is commonly suggested to manage breakthrough pain. A comparative study of intravenous morphine (IV-MO) and oral transmucosal fentanyl citrate (OTFC) given in doses proportional to the basal opioid regimen was performed in 25 cancer patients receiving stable opioid doses. For each episode, when it occurred and 15 and 30 min after the treatment, pain intensity and opioid-related symptoms were recorded. Fifty-three couples of breakthrough events, each treated with IV-MO and OTFC, were recorded. In episodes treated with IV-MO, pain intensity decreased from a mean of 6.9 to 3.3 and to 1.7 at T1 and T2, respectively. In episodes treated with OTFC, pain int…

AdultMalecancer painCancer Researchintravenous morphineAdolescentTransmucosal fentanyl; intravenous morphine; episodic-breakthrough pain.Transmucosal fentanylAdministration OralPainFentanylNeoplasmsClinical StudiesmedicineHumansDosingChildOTFCAdverse effectCross-Over StudiesMorphinebusiness.industryInfantopioidsMiddle Agedbreakthrough painCrossover studyAnalgesics OpioidFentanylRegimenepisodic-breakthrough pain.OncologyOpioidChild PreschoolAnesthesiaInjections IntravenousMorphineFemalebusinessCancer painmedicine.drugBritish Journal of Cancer
researchProduct

Endotheliopathy in obstetric emergencies

2006

researchProduct

Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain.

2005

Patients who experience a poor response to different systemic opioid trials (oral and intravenous) are candidates for spinal treatment. Breakthrough pain occurring in this group of patients is challenging for physicians. This phenomenon has never been described in this context and the treatment is quite difficult, as patients already demonstrated a poor response to systemic opioids. We report a preliminary experience of alternative methods, including the intrathecal injection of local anesthetic boluses as needed, or alternatively, the use of sublingual ketamine. Twelve consecutive patients with advanced cancer and pain were selected for intrathecal treatment after receiving different trial…

AdultMalemedicine.medical_specialtymedicine.drug_classPopulationAnalgesicAdministration SublingualPainNeoplasmsmedicineHumansKetamineAnesthetics LocaleducationGeneral NursingInjections SpinalAgedLevobupivacaineeducation.field_of_studyAnalgesicsbusiness.industryLocal anestheticMiddle AgedBupivacaineSurgeryAnesthesiology and Pain MedicineLevobupivacaineOpioidAnesthesiaMorphineFemaleKetamineNeurology (clinical)businessCancer painmedicine.drugJournal of pain and symptom management
researchProduct

TLR4 upregulation underpins airway neutrophilia in smokers with chronic obstructive pulmonary disease and acute respiratory failure

2010

Activation of Toll-like receptors (TLR) seems to be involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). Upon TLR activation the release of defensins, including human beta defensin 2 (HBD-2), may occur. In this study, we explored the innate responses in patients with respiratory failure, with and without COPD, requiring intubation and mechanical ventilation. Mini-bronchoalveolar lavage (mini-BAL) samples were collected from nonsmoker subjects without COPD (n = 10), smokers without COPD (n = 6), and smokers with COPD (n = 15). TLR4, TLR2, and HBD-2 expression was evaluated by immunocytochemistry; interleukin (IL)-8, IP-10, and HBD-2 concentrations were evaluated by e…

MaleChemokinebeta-DefensinsLeukocytosisNeutrophilsLymphocyteImmunologySettore MED/41 - AnestesiologiaApoptosisPathogenesisPulmonary Disease Chronic ObstructivemedicineHumansImmunology and AllergyAgedAged 80 and overCOPDTUNEL assaybiologybusiness.industryChemotaxisInterleukin-8SmokingAcute Lung Injury COPD TLR4InterleukinGeneral Medicinemedicine.diseaseToll-Like Receptor 2Neutrophiliarespiratory tract diseasesToll-Like Receptor 4medicine.anatomical_structureTerminal deoxynucleotidyl transferaseAcute DiseaseImmunologybiology.proteinFemalemedicine.symptomRespiratory InsufficiencybusinessBronchoalveolar Lavage FluidHuman Immunology
researchProduct

Alternative Treatments of Breakthrough Pain in Patients Receiving Spinal Analgesics for Cancer Pain

2005

researchProduct

Il ruolo della tromboelastografia (TEG) nel paziente settico in corso di trattamento con inibitori della coagulazione

2004

researchProduct